Trump unveils Regeneron pact to lower Medicaid drug costs
TL;DR
President Trump announced a deal with Regeneron to reduce prices on all Regeneron drugs sold on Medicaid, including Praluent at $225 on the TrumpRx site, as part of a broader White House drug-pricing push. Regeneron also pledged about $27 billion in U.S. R&D/manufacturing investments. Details of the contracts remain largely undisclosed, but the administration is promoting the agreements ahead of the midterm elections as part of its effort to reshape U.S. drug pricing.
- WATCH: Trump unveils deal with Regeneron to lower its drug prices for Medicaid PBS
- Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free CNBC
- 2-year-old joins Trump at White House as president spotlights 'miracle cure' for deaf boy KOMO
- Regeneron to offer prescriptions at most favored nation prices, Trump says Reuters
- Trump celebrates closing first round of drug pricing deals, promises more ahead statnews.com
Want the full story? Read the original reporting
Read on PBS